Sugi Predict

Sugi Predict / Compounds / SCHEMBL6154243

SCHEMBL6154243

SCHEMBL6154243

O[C@H](CCl)COCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 5/20 0.68
▸ CA2 P00918 3/20 0.68
▸ CA7 P43166 3/20 0.68
▸ CA9 Q16790 3/20 0.68
▸ MAPK1 P28482 1/20 0.54
▸ TSHR P16473 2/20 0.52
▸ POLB P06746 1/20 0.49
▸ PRMT5 O14744 1/20 0.49
▸ WDR77 Q9BQA1 1/20 0.49
▸ CYP1A2 P05177 1/20 0.49
▸ CYP3A4 P08684 1/20 0.49
▸ CYP2D6 P10635 1/20 0.49
▸ CYP2C9 P11712 1/20 0.49
▸ CYP2C19 P33261 1/20 0.49
▸ AGER Q15109 1/20 0.49
▸ TACR1 P25103 2/20 0.47
▸ CA4 P22748 1/20 0.47
▸ KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5467608 1.00 CA1 (0.68) CA1CA2CA7CA9MAPK1
SCHEMBL3647026 1.00 CA1 (0.68) CA1CA2CA7CA9MAPK1
SCHEMBL397022 0.88 CA1 (0.78) CA1CA2CA7CA9MAPK1
SCHEMBL7153591 0.84 CA1 (0.76) CA1CA2CA7CA9MAPK1
SCHEMBL23258692 0.82 CA1 (0.70) CA1CA2CA7CA9MAPK1
SCHEMBL122306 0.82 CA1 (0.70) CA1CA2CA7CA9MAPK1
SCHEMBL218661 0.82 CA1 (0.70) CA1CA2CA7CA9MAPK1
SCHEMBL16269805 0.82 CA1 (0.70) CA1CA2CA7CA9MAPK1
SCHEMBL508126 0.82 CA1 (0.70) CA1CA2CA7CA9MAPK1
Phenol SCHEMBL28469017 0.82 CA1 (0.46) CA1CA2CA7CA9MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240173305-A1 RAPAMYCIN ANALOGS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-05-30 — — US disclosed
EP-3813946-B1 RAPAMYCIN ANALOGS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-05-22 — — EP disclosed
CN-117843659-A Rapamycin analogues and uses thereof 詹森药业有限公司 2024-04-09 — — CN disclosed
US-11944605-B2 Rapamycin analogs and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-04-02 — — US disclosed
EP-4302827-A2 RAPAMYCIN ANALOGS AND USES THEREOF JANSSEN Pharmaceutica NV (BE) 2024-01-10 — — EP disclosed
CN-112423843-B Rapamycin analogues and uses thereof 詹森药业有限公司 2023-11-28 — — CN disclosed
US-20210220339-A1 RAPAMYCIN ANALOGS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2021-07-22 — — US disclosed
US-20210220339-A1 RAPAMYCIN ANALOGS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2021-07-22 — — US disclosed
EP-3813946-A1 RAPAMYCIN ANALOGS AND USES THEREOF Navitor Pharmaceuticals, Inc. (US) 2021-05-05 — — EP disclosed
US-10980784-B2 Rapamycin analogs and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2021-04-20 — — US disclosed
US-10980784-B2 Rapamycin analogs and uses thereof NAVITOR PHARMACEUTICALS, INC. (US) 2021-04-20 — — US disclosed
CN-112423843-A Rapamycin analogs and uses thereof 纳维托制药有限公司 2021-02-26 — — CN disclosed
EP-1298119-A4 CHLOROHYDROXYACETONE DERIVATIVE AND PROCESS FOR PRODUCING OPTICALLY ACTIVE CHLOROPROPANEDIOL DERIVATIVE FROM THE SAME KANEKA CORP (JP) 2005-09-21 — — EP disclosed
US-6682916-B2 CHEMICAL INTERMEDIATE FOR DRUGS; REDUCTION USING ENZYME KANEKA CORPORATION (JP) 2004-01-27 — — US disclosed
US-6682916-B2 CHEMICAL INTERMEDIATE FOR DRUGS; REDUCTION USING ENZYME KANEKA CORPORATION (JP) 2004-01-27 — — US disclosed
EP-1298119-A1 CHLOROHYDROXYACETONE DERIVATIVE AND PROCESS FOR PRODUCING OPTICALLY ACTIVE CHLOROPROPANEDIOL DERIVATIVE FROM THE SAME KANEKA CORPORATION (JP) 2003-04-02 — — EP disclosed
EP-1298119-A1 CHLOROHYDROXYACETONE DERIVATIVE AND PROCESS FOR PRODUCING OPTICALLY ACTIVE CHLOROPROPANEDIOL DERIVATIVE FROM THE SAME KANEKA CORPORATION (JP) 2003-04-02 — — EP disclosed
US-20020160398-A1 Chlorohydroxyacetone derivative and process for producing optically active chloropropanediol derivative from the same KANEKA CORPORATION (JP) 2002-10-31 — — US disclosed
US-20020160398-A1 Chlorohydroxyacetone derivative and process for producing optically active chloropropanediol derivative from the same KANEKA CORPORATION (JP) 2002-10-31 — — US disclosed
WO-2002000585-A1 CHLOROHYDROXYACETONE DERIVATIVE AND PROCESS FOR PRODUCING OPTICALLY ACTIVE CHLOROPROPANEDIOL DERIVATIVE FROM THE SAME KANEKA CORPORATION (JP) 2002-01-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10980784-B2 Rapamycin analogs and uses thereof RICTOR, MTOR, RPTOR CA1 4755/4885CA2 4583/4885CA7 3767/4885
US-20210220339-A1 RAPAMYCIN ANALOGS AND USES THEREOF RICTOR, MTOR, RPTOR CA1 4755/4885CA2 4583/4885CA7 3767/4885
US-11944605-B2 Rapamycin analogs and uses thereof RICTOR, MTOR, RPTOR CA1 4755/4885CA2 4583/4885CA7 3767/4885
US-20240173305-A1 RAPAMYCIN ANALOGS AND USES THEREOF RICTOR, MTOR, RPTOR CA1 4755/4885CA2 4583/4885CA7 3767/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.